Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a small portion of the extracted claims can be mapped to the limited provided label text (5.12). Most claims are left unsupported/unverified, and high-priority label elements (e.g., contraindications, boxed warnings, dosage, specific populations, adverse reactions) are not evaluated, preventing confirmation of on-label accuracy.
Category Scores
Accurate Statements
Prescribing TYGACIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of the development of drug-resistant bacteria.
5 WARNINGS AND PRECAUTIONS, 5.12 Development of Drug-Resistant Bacteria (verbatim provided)
Unsupported Statements
Tigecycline is a broad-spectrum antibiotic.
No supporting text for this claim is present in the supplied label sections.
Tigecycline is a glycylcycline antibiotic.
No supporting text for this claim is present in the supplied label sections.
Tigecycline was approved in 2005 for treatment of complicated skin and skin structure infections (cSSSI).
No supporting text for approval year or indication history is present in the supplied label sections.
Tigecycline was approved in 2005 for treatment of community-acquired bacterial pneumonia (CABP).
No supporting text for approval year or indication history is present in the supplied label sections.
As tigecycline use increased, tigecycline-resistant strains emerged.
No supporting text for emergence related to increased use is present in the supplied label sections.
Development of tigecycline resistance can increase morbidity.
The supplied label text only addresses increased risk of drug-resistant bacteria with inappropriate prescribing; it does not support morbidity.
Development of tigecycline resistance can increase mortality.
The supplied label text does not support mortality.
Spread of tigecycline-resistant bacteria can compromise the effectiveness of other antibiotics.
No supporting text for impact on other antibiotics is present in the supplied label sections.
Stewardship programs aim to optimize the use of antibiotics, including tigecycline, to prevent the development of resistance.
Stewardship strategy language is not directly stated in the supplied label sections.
Antibiotic formulary management can restrict access to antibiotics such as tigecycline to only those patients who truly need them.
No supporting text for formulary management mechanisms is present in the supplied label sections.
Surveillance and monitoring of antibiotic use and resistance patterns can inform stewardship strategies for antibiotics including tigecycline.
No supporting text for surveillance/monitoring informing stewardship is present in the supplied label sections.
A hospital stewardship program reduced tigecycline use by 43%.
No quantitative outcome evidence is present in the supplied label sections.
A hospital stewardship program decreased the incidence of tigecycline-resistant infections by 25%.
No quantitative outcome evidence is present in the supplied label sections.
Stewardship programs have been shown to reduce antibiotic use.
No supporting text in the supplied label sections.
Stewardship programs have been shown to prevent the development of resistance.
The supplied label text addresses risk of drug-resistant bacteria with inappropriate prescribing; it does not support the broader 'shown to prevent' framing.
Contradictions
Important Omissions
Evaluation for contraindications, boxed warnings, dosage/administration, adverse reactions, drug interactions, and use in specific populations was not performed because those label elements are not included in the provided label sections for assessment.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
While the supplied label text (5.12) supports the general risk of resistance with inappropriate prescribing, most other claims are not supported/verified against the provided label excerpts. Unverified or overly specific claims could mislead interpretation of on-label risks and benefits.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most extracted claims are unsupported by the limited provided label text, and key FDA label elements were not assessed.
Suggested Improvement
Limit assertions to statements directly supported by the provided label sections (or provide additional label sections for evaluation), and avoid unverified claims about spectrum/classification, approval history, quantitative stewardship outcomes, and broader effects not present in 5.12.